Visante hires pharmacy revenue cycle expert Adrianne “Maxie” Friemel to expand growing consulting service practice

Visante Inc. announces that Adrianne (Maxie) Friemel (PharmD, MS, BCPS, CRCR) has joined the firm as Senior Director, Pharmacy Revenue Cycle Services.

Visante says these Friemel’s deep, contemporary expertise will expand capabilities in its quickly growing consulting areas of pharmacy revenue cycle, drug reimbursement, and pharmacy financial integrity. These areas of expertise help hospitals, health systems and integrated delivery networks to greatly improve financial and operational performance for the entire organization.

“Maxie brings a very unique expertise in the marketplace in an area where many health systems have immense opportunity for better integrity and performance. Her addition to the Visante team highlights our focus on the business of pharmacy, and continues to promote our efforts to help our partners achieve success in the pharmacy revenue cycle space,” said Joe Cesarz, Visante VP.Jim Jorgenson, CEO of Visante, commented, “The experience and expertise that Maxie brings to our group is really fantastic for our clients. Her approach to pharmacy revenue cycle is innovative and forward-thinking. She has incredible knowledge and her experience is going to be a huge asset to help clients achieve a high-performing pharmacy enterprise. “

Maxie Friemel will support Visante partners in all aspects of pharmacy revenue cycle. Prior to joining Visante, she was the Manager of Revenue Integrity for Pharmacy and Oncology at SCL Health where she oversaw both services lines of pharmacy and oncology revenue cycles for over five years. Friemel designed and developed the concept of Revenue Practice Teams which treated revenue cycle as a service line and engaged multiple interdisciplinary teams to better optimize front to back-end processes. She was previously the Manager of Supply Chain and Transitional Care at UW Health and Chartwell Home Infusion. Friemel is a well-respected author, speaker and blogger in pharmacy revenue cycle.